Liposome-encapsulated hemoglobin ameliorates impairment of fear memory and hypocampal dysfunction after cerebral ischemia in rats

  • Hamadate Naobumi
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Yamaguchi Taku
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Sugawara Aya
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Togashi Hiroko
    Department of Pharmacology, Faculty of Pharmaceutical Science, Health Science University of Hokkaido, Japan
  • Izumi Takeshi
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Yoshida Takayuki
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Ohmura Yu
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan
  • Yoshioka Mitsuhiro
    Department of Neuropharmacology, Hokkaido University Graduate School of Medicine, Japan

書誌事項

タイトル別名
  • Liposome-Encapsulated Hemoglobin Ameliorates Impairment of Fear Memory and Hippocampal Dysfunction After Cerebral Ischemia in Rats

この論文をさがす

抄録

Liposome-encapsulated hemoglobin (LEH) has been developed as a blood substitute. In spite of its size (1/30 – 1/40 of erythrocytes), LEH has an oxygen-carrying capacity comparable to erythrocytes. Thus, LEH is expected to carry oxygen into vital organs via collateral routes during ischemia induced by vascular embolism. In the present study, we examined the therapeutic effects of LEH on behavioral impairments in rats after four-vessel occlusion (4VO) for 30 min. In the open-field test, locomotor activity in 4VO rats did not alter 7 days after ischemia. However, in the contextual fear conditioning (CFC) test, the freezing rate was significantly decreased in 4VO rats, although no behavioral changes in the Y-maze test and elevated plus-maze test were observed. Phosphorylation of the cyclic AMP response element-binding protein (CREB) in the hippocampal CA1 region after the CFC test was attenuated. These 4VO-induced impairments were significantly alleviated by the administration of LEH (5 ml/kg, i.v.) during occlusion. Moreover, LEH did not alter hippocampal blood flow and tissue oxygen pressure during 4VO, but it did suppress hyperoxia after ischemia–reperfusion. These findings suggest that LEH, an artificial oxygen carrier, could be a novel therapeutic agent for brain dysfunction after acute cerebral ischemia.

収録刊行物

被引用文献 (7)*注記

もっと見る

参考文献 (117)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ